

SWOG Clinical Trials Partnerships (CTP)

HOW SWOG PARTNERS WITH INDUSTRY TO CONDUCT CANCER CLINICAL TRIALS

SWOG CTP Update Forum

THURSDAY, APRIL 30 • 5:30 – 6:30 PM PT • GRAND BALLROOM A (STREEL LEVEL) & ONLINE

- **SWOG CTP overview**

- Joint study development process
- Scientific areas of interest
- Types of trials

- **SWOG CTP active trials**

- **21CTP.LEUK01:** Phase II trial for patients with newly diagnosed Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia
- **21CTP.HN01 (CAPT-HN):** Phase II study in recurrent metastatic head and neck cancer with cohorts defined by type of and/or response to prior systemic therapies



To apply to open either study, complete its feasibility survey at swogctp.org/trials.

- **Accrual completed: TROPION Breast 03 FDA registration trial**

- **SWOG CTP trials in development:**

- **21CTP.BREAST01 (MONITOR):** Phase II platform trial using circulating tumor DNA to monitor treatment response in HR+, HER2- metastatic breast cancer
- **26CTP.LEUK02 (APEX-MF):** Randomized open label trial for treatment-naïve, cytopenic myelofibrosis
- **26CTP.BMT01:** HA-1 TCR T cell phase II treatment trial

- **Site logistics: operations & data management**

- Feasibility survey outreach and site selection
- Site funding and contracts
- Site activation process and engagement
- Lessons learned

- **Novel CTP projects and other collaborative opportunities**

All are invited!

Learn more: swogctp.org

Email us: CTP@swog.org

For a one-on-one appointment with our Research Site Coordination Manager: sitecoordination@swogctp.org